Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OrthoSensor, Inc.
CTMC CEO Jason Bock talked to Scrip about the venture between MD Anderson and National Resilience, which provides manufacturing, process development and regulatory support for small cell therapy developers’ preclinical and clinical proof-of-concept studies. Meanwhile, Verge Genomics initiated a Phase Ib study of its AI-discovered drug for ALS; EyePoint and Aviceda dosed patients in their Phase II DME trials; Parexel teamed up with a non-profit cancer research group in Japan; and BARDA selected PPD to run its Phase II platform trial for ARDS.
Zimmer Biomet and Canary Medical’s FDA de novo clearance of the Persona IQ total knee implant intensifies Zimmer Biomet’s focus on data collection and analytics across continuum of care to improve outcomes and surgery methods, an analyst wrote.
OrthoSensor’s sensor technology complements Stryker’s robotic surgery platform, improves its data-analytics capabilities, and contributes to the development of orthopedic implants with integrated sensors.
The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.
- Digital Health
- Implantable Devices
- Monitoring Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.